You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline

You are reading 1 of 2 free-access articles allowed for 30 days

Collaborating for improvements in cardiac care

By Mindo - 24th Apr 2019 | 8 views


The Cardiology on the Green conference, held in the RCSI on 4-6 April 2019, was the inaugural joint meeting between the Irish Cardiac Society (ICS) and the Mayo Clinic, US, and marked 70 years since the establishment of the ICS.

The conference hosted a range of distinguished national and international speakers, all of whom are renowned experts in their fields.

The first session was chaired by Dr Barry Boilson of the Mayo Clinic and Prof Ken McDonald, Consultant Cardiologist at St Vincent’s University Hospital in Dublin.

Dr Jim Crowley, ICS President, opened the conference, referring to the “great opportunity” provided by the meeting to enhance professional contacts and exchange clinical expertise. Dr Boilson added that there had been “tremendous excitement” building in the Mayo Clinic at the prospect of the meeting, adding that it presented an important building-block for future collaboration between the two bodies.

The attendees first heard from Prof McDonald, who addressed issues in natriuretic peptides in cardiology and provided an overview of the STOP-HF trial. “Because of the onslaught of heart failure (HF), and because we continue to fail to produce an effective therapy for HF with preserved systolic function — although we may have something by the end of the year as a result of the PARAGON study — we realised that there is a need to start preventing HF,” he stated.

Prof Ken McDonald

Prof McDonald, who was one of the people instrumental in setting-up the conference, pointed out that approximately one-fifth to one-sixth of the population are at risk of developing HF and he presented “very concerning” data to show that stage B HF is now more dominant at the age of 50 years than normal status. “There has been excellent work by numerous people… to show that natriuretic peptide, above all other cardiovascular (CV) risk indicators, sets out the risk for HF. However, interestingly, and relevant to the STOP-HF data, it also sets out the risk of cardiovascular disease in general, so it stands out as the risk indicator for CV disease above all other risk factors.”


The meeting next heard from Dr Valentina Cannone, Assistant Professor of Medicine at the Mayo Clinic, who collaborated with Prof McDonald on the STOP-HF trial and spoke on the topic: ‘Overview of Collaborative Work between St Vincent’s University Hospital and the Mayo Clinic’. Dr Cannone told the attendees: “In this trial, we approached BNP from a different perspective — as a cardiac hormone secreted by the heart as a compensatory response to volume overload.”

BNP induces natriuresis and has a vasodilatory effect, and can also inhibit the renin-angiotensin-aldosterone system, she explained, as well as inhibiting cardiac fibrosis and cardiac hypertrophy.

Dr Cannone, outlining the recent work in her laboratory, stated: “This study supports the concept that there might be a cardiovascular protective effect exerted by the genetic variant rs198389 and BNP circulating levels associated with this genetic variant. But importantly, our study also supports the idea that augmenting the BNP system may have a cardioprotective, therapeutic effect in the prevention of HF.”

Leave a Reply

Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read